Account Information

bundle-connector

secondary-primary-menu

footer-legal-menu-component

secondary-account-menu

header-component

footer

products

secondary-storefront-menu

Marketing materials, training documents, discovery services

cengage:card

FIND YOUR SALES REPRESENTATIVE

cengage:column

Get marketing materials, training documents, discovery services.

PRODUCT SUPPORT

CUSTOMER SUPPORT

Report technical issues, errors, check system status

TECHNICAL SUPPORT

Manage product preferences, generate usage reports, simplify administrative tasks.

ADMIN TOOLS

support

zone1

cengage:galethorndikeseo

container

mega-menu

single-column

footer-social-menu-component

Would you like to go to the Gale {{RECOMMENDED_COUNTRY}} site instead?

It looks like you're visiting from {{DETECTED_COUNTRY}}.

main

footer-legal-menu

Terms of use

Privacy

header

zone2

gale-footer

About Us

Blogs

Press Center

Events

News

Careers

Our Company

Request a Trial

footer-menu-component

%1 products have been added to your cart but %2 have been backordered and will be fulfilled when stock is available

Product on backorder

Current quantity limit is [maxProductQuantity], please, navigate to the cart page and change quantity of product

You will be able to resubmit promo in ${countdown} seconds. test

Please note that the taxes displayed on our website are estimated and subject to adjustment. The actual tax charges will be determined and settled during the final invoicing of your order

product-detail-component

FIND YOUR REP

support-order-2

International

North America

China

Japan

Latin America

Brazil

Region

Set your region:

footer-social-menu

Sign Up for Emails

CONNECT WITH GALE

Stay up-to-date with the latest Gale news, exclusive offers, and more.

facebook

linkedin

instagram

youtube

SOCIAL ICONS

footer-menu

Academic Institutions

K-12

Public Libraries

Government and Special Libraries

Statewide Programs

Institutions

Databases

Primary Sources

Digital Humanities Tools

eLearning

Schools/K-12 Curriculum

Books

Large Print Books by Thorndike Press

Products

Find Your Rep

Product Support

Technical Support

Customer Support

Admin Tools

Accessibility Policy

Support

Partnerships

Contact Us

Profile

Orders

Wish List

Fast Order Entry

My Account

config

You may already have access to Gale content through your institution.

STUDENTS AND RESEARCHERS

support-order-1

zone3

Browse by Institution Type

Browse by Product Type

Diseases & Conditions

Health, Medicine & Nursing

Gt Product Group

Binding Format

Marketing Imprint Name

B2B GT

CL Carton Count

Imprint Name

B2B & B2C

Gene therapy as a treatment for cancer is at a critical point. Exciting new developments, coupled with results from the first generation of studies have led to design and testing of new approaches. The Third Edition of Gene Therapy of Cancer is a comprehensive assessment of the field including suicide gene therapy, oncogene and suppressor gene targeting, and drug resistance gene therapy. Researchers at all levels will find this book e instructive. Cancer gene therapy is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of  tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. Gene therapy for cancer can form a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector-based gene delivery; the use of viral and gene-based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or immune response.

Gene Therapy of Cancer

POST SECONDARY FOUR YEAR

COLFR

COLSO

COLJR

COLSR

GENE THERAPY OF CANCER 3

Duration

Duration Unit Of Measure

Transaction Type

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
Dedication.
Contents.
List of Contributors.
1: Viral and Nonviral Vector Methodologies: Targets and Approaches.
2: Ex Vivo Gene Therapy Utilization of Genetic Vectors for the Generation of Genetically Modified Cell Products for Therapy.
3: Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factor-&#x03B1;.
4: Viral Insertion Site Detection and Analysis in Cancer Gene Therapy.
5: Targeted Systemic Delivery of Therapeutic siRNA.
6: Bacterial Delivery of RNAi Effectors.
7: Gene-Directed Enzyme Prodrug Cancer Therapy.
8: Electroporation Gene Therapy.
9: Toxin-Based Cancer Gene Therapy Under the Control of Oncofetal H19 Regulatory Sequences.
10: Gene Therapy in Radiotherapy of Cancer.
11: Oncolytic Viruses.
12: Advances in Oncolytic Virotherapy for Brain Tumors.
13: Oncolytic Adenoviruses in the Treatment of Cancer in Humans1.
14: Selectively Replicating Oncolytic Adenoviruses Combined with Chemotherapy, Radiotherapy, or Molecular Targeted Therapy for Treatment of Human Cancers.
15: Reoviral Therapy for Cancer Strategies for Improving Antitumor Efficacy Using Radio- and Chemotherapy.
16: Selectively Replicating Herpes Simplex Viral Vectors.
17: Modified Oncolytic Herpesviruses for Gene Therapy of Cancer.
18: The Lister Strain of Vaccinia Virus as an Anticancer Therapeutic Agent.
19: Immunotherapeutics.
20: Poxvirus-Based Strategies for Combined Vaccine and Tumor Microenvironment Manipulation.
21: Genetically Engineered (T Cell Receptor) T Cells for Adoptive Therapy.
22: Genetically Modified Dendritic Cell Vaccines for Solid Tumors.
23: Dendritic Cell Vaccination.
24: Chemokine Gene-Modified Dendritic Cells for Cancer Therapy.
25: The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors.
26: Clinical Application of Plasmid-Based Cancer Vaccines.
27: Lentivector Vaccines.
28: Therapeutic Efficacy and Systemic Antitumor T Cell Immunity Induced by RheoSwitch-Regulated IL-12 Expression after Intratumoral Injection of Adenovirus Vector or Vector-Transduced Dendritic Cells.
29: Drug Resistance and Metabolism Gene Therapy.
30: Clinical Trials Using LV-P140K-MGMT for Gliomas.
31: RNA Interference Therapeutics for Tumor Therapy: Promising Work in Progress.
32: MGMT Stem Cell Selection and Protection: Preclinical Large Animal and Clinical Studies.
33: Cytidine Deaminase in Myeloprotective Gene Therapy.
34: Cancer Therapy Imaging Vectors.
35: Genetically Engineered Salmonella typhimurium for Targeted Cancer Therapy.
36: Imaging of Oncolytic Virus Gene Expression.
37: Lentiviral-Encoded Sodium Iodide Symporter-Mediated Cancer Gene Therapy.
38: Bacteriophage From Bacteria to a Successful Targeted Systemic Gene Delivery for Cancer.
39: Issues in Trial Design Review and Approval.
40: Issues in Moving Gene Therapy Approaches to Early Clinical Trials.
41: The FDA Review Process for Cancer Gene Therapy.
42: Ethics in Translational Gene Transfer Research.
Index.

Gene Therapy of Cancer.css-1p8rvzy{position:absolute;padding-left:8px;}

Gene Therapy of Cancer